Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors.

Radi M, Falchi F, Garbelli A, Samuele A, Bernardo V, Paolucci S, Baldanti F, Schenone S, Manetti F, Maga G, Botta M.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):2094-8. doi: 10.1016/j.bmcl.2011.12.135.

PMID:
22300661
2.

Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation.

Maga G, Falchi F, Radi M, Botta L, Casaluce G, Bernardini M, Irannejad H, Manetti F, Garbelli A, Samuele A, Zanoli S, Esté JA, Gonzalez E, Zucca E, Paolucci S, Baldanti F, De Rijck J, Debyser Z, Botta M.

ChemMedChem. 2011 Aug 1;6(8):1371-89. doi: 10.1002/cmdc.201100166.

PMID:
21698775
3.

Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication.

Garbelli A, Radi M, Falchi F, Beermann S, Zanoli S, Manetti F, Dietrich U, Botta M, Maga G.

Curr Med Chem. 2011;18(20):3015-27. Review.

PMID:
21651478
4.
5.

Homology Model-Based Virtual Screening for the Identification of Human Helicase DDX3 Inhibitors.

Fazi R, Tintori C, Brai A, Botta L, Selvaraj M, Garbelli A, Maga G, Botta M.

J Chem Inf Model. 2015 Nov 23;55(11):2443-54. doi: 10.1021/acs.jcim.5b00419.

PMID:
26544088
6.

A motif unique to the human DEAD-box protein DDX3 is important for nucleic acid binding, ATP hydrolysis, RNA/DNA unwinding and HIV-1 replication.

Garbelli A, Beermann S, Di Cicco G, Dietrich U, Maga G.

PLoS One. 2011 May 12;6(5):e19810. doi: 10.1371/journal.pone.0019810.

7.

Knockdown of cellular RNA helicase DDX3 by short hairpin RNAs suppresses HIV-1 viral replication without inducing apoptosis.

Ishaq M, Hu J, Wu X, Fu Q, Yang Y, Liu Q, Guo D.

Mol Biotechnol. 2008 Jul;39(3):231-8. doi: 10.1007/s12033-008-9040-0.

PMID:
18259889
8.

Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function.

Yedavalli VS, Neuveut C, Chi YH, Kleiman L, Jeang KT.

Cell. 2004 Oct 29;119(3):381-92.

9.

Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM.

N Engl J Med. 1999 May 27;340(21):1614-22.

10.

Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein.

Zentner I, Sierra LJ, Fraser AK, Maciunas L, Mankowski MK, Vinnik A, Fedichev P, Ptak RG, Martín-García J, Cocklin S.

ChemMedChem. 2013 Mar;8(3):426-32. doi: 10.1002/cmdc.201200577.

PMID:
23361947
11.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
13.
14.

Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication.

Thenin-Houssier S, de Vera IM, Pedro-Rosa L, Brady A, Richard A, Konnick B, Opp S, Buffone C, Fuhrmann J, Kota S, Billack B, Pietka-Ottlik M, Tellinghuisen T, Choe H, Spicer T, Scampavia L, Diaz-Griffero F, Kojetin DJ, Valente ST.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2195-208. doi: 10.1128/AAC.02574-15.

15.

Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy.

Romano L, Venturi G, Catucci M, De Milito A, Valensin PE, Zazzi M.

J Infect Dis. 1999 Feb;179(2):361-6.

PMID:
9878019
16.

DDX3 DEAD-Box RNA helicase inhibits hepatitis B virus reverse transcription by incorporation into nucleocapsids.

Wang H, Kim S, Ryu WS.

J Virol. 2009 Jun;83(11):5815-24. doi: 10.1128/JVI.00011-09.

17.

Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.

Paolucci S, Baldanti F, Campanini G, Zavattoni M, Cattaneo E, Dossena L, Gerna G.

J Med Virol. 2001 Oct;65(2):207-17.

PMID:
11536225
18.

Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients.

De Milito A, Catucci M, Venturi G, Romano L, Incandela L, Valensin PE, Zazzi M.

J Med Virol. 1999 Feb;57(2):140-4.

PMID:
9892398
19.

DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication.

Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, Kato N.

J Virol. 2007 Dec;81(24):13922-6.

20.

Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.

Parisi SG, Boldrin C, Cruciani M, Nicolini G, Cerbaro I, Manfrin V, Dal Bello F, Franchin E, Franzetti M, Rossi MC, Cattelan AM, Romano L, Zazzi M, Andreoni M, Palù G.

J Clin Microbiol. 2007 Jun;45(6):1783-8. Erratum in: J Clin Microbiol. 2007 Oct;45(10):3484.

Supplemental Content

Support Center